PMC:7091888 / 22147-22578 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"922","span":{"begin":0,"end":8},"obj":"Species"},{"id":"923","span":{"begin":55,"end":65},"obj":"Species"},{"id":"924","span":{"begin":141,"end":149},"obj":"Species"},{"id":"925","span":{"begin":240,"end":248},"obj":"Species"},{"id":"926","span":{"begin":264,"end":274},"obj":"Species"},{"id":"927","span":{"begin":398,"end":408},"obj":"Species"},{"id":"929","span":{"begin":91,"end":123},"obj":"Disease"},{"id":"930","span":{"begin":203,"end":223},"obj":"Disease"},{"id":"931","span":{"begin":412,"end":430},"obj":"Disease"}],"attributes":[{"id":"A922","pred":"tao:has_database_id","subj":"922","obj":"Tax:694009"},{"id":"A923","pred":"tao:has_database_id","subj":"923","obj":"Tax:2697049"},{"id":"A924","pred":"tao:has_database_id","subj":"924","obj":"Tax:694009"},{"id":"A925","pred":"tao:has_database_id","subj":"925","obj":"Tax:694009"},{"id":"A926","pred":"tao:has_database_id","subj":"926","obj":"Tax:2697049"},{"id":"A927","pred":"tao:has_database_id","subj":"927","obj":"Tax:2697049"},{"id":"A929","pred":"tao:has_database_id","subj":"929","obj":"MESH:C000657245"},{"id":"A930","pred":"tao:has_database_id","subj":"930","obj":"MESH:C000657245"},{"id":"A931","pred":"tao:has_database_id","subj":"931","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"SARS-CoV RBD-induced antibodies could cross-react with SARS-CoV-2 RBD and cross-neutralize SARS-CoV-2 pseudovirus infection, indicating that SARS-CoV RBD-specific antibodies may be used for treatment of SARS-CoV-2 infection and that either SARS-CoV RBD protein or SARS-CoV-2 RBD protein may be used as a candidate vaccine to induce cross-reactive or cross-neutralizing antibodies for prevention of SARS-CoV-2 or SARS-CoV infection."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T174","span":{"begin":253,"end":260},"obj":"Body_part"},{"id":"T175","span":{"begin":279,"end":286},"obj":"Body_part"}],"attributes":[{"id":"A174","pred":"fma_id","subj":"T174","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A175","pred":"fma_id","subj":"T175","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"SARS-CoV RBD-induced antibodies could cross-react with SARS-CoV-2 RBD and cross-neutralize SARS-CoV-2 pseudovirus infection, indicating that SARS-CoV RBD-specific antibodies may be used for treatment of SARS-CoV-2 infection and that either SARS-CoV RBD protein or SARS-CoV-2 RBD protein may be used as a candidate vaccine to induce cross-reactive or cross-neutralizing antibodies for prevention of SARS-CoV-2 or SARS-CoV infection."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T411","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T412","span":{"begin":0,"end":4},"obj":"Disease"},{"id":"T413","span":{"begin":55,"end":63},"obj":"Disease"},{"id":"T414","span":{"begin":55,"end":59},"obj":"Disease"},{"id":"T415","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"T416","span":{"begin":91,"end":95},"obj":"Disease"},{"id":"T417","span":{"begin":114,"end":123},"obj":"Disease"},{"id":"T418","span":{"begin":141,"end":149},"obj":"Disease"},{"id":"T419","span":{"begin":141,"end":145},"obj":"Disease"},{"id":"T420","span":{"begin":203,"end":211},"obj":"Disease"},{"id":"T421","span":{"begin":203,"end":207},"obj":"Disease"},{"id":"T422","span":{"begin":214,"end":223},"obj":"Disease"},{"id":"T423","span":{"begin":240,"end":248},"obj":"Disease"},{"id":"T424","span":{"begin":240,"end":244},"obj":"Disease"},{"id":"T425","span":{"begin":264,"end":272},"obj":"Disease"},{"id":"T426","span":{"begin":264,"end":268},"obj":"Disease"},{"id":"T427","span":{"begin":398,"end":406},"obj":"Disease"},{"id":"T428","span":{"begin":398,"end":402},"obj":"Disease"},{"id":"T429","span":{"begin":412,"end":430},"obj":"Disease"},{"id":"T430","span":{"begin":412,"end":416},"obj":"Disease"},{"id":"T431","span":{"begin":421,"end":430},"obj":"Disease"}],"attributes":[{"id":"A411","pred":"mondo_id","subj":"T411","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A412","pred":"mondo_id","subj":"T412","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A413","pred":"mondo_id","subj":"T413","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A414","pred":"mondo_id","subj":"T414","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A415","pred":"mondo_id","subj":"T415","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A416","pred":"mondo_id","subj":"T416","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A417","pred":"mondo_id","subj":"T417","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A418","pred":"mondo_id","subj":"T418","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A419","pred":"mondo_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A420","pred":"mondo_id","subj":"T420","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A421","pred":"mondo_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A422","pred":"mondo_id","subj":"T422","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A423","pred":"mondo_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A424","pred":"mondo_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A425","pred":"mondo_id","subj":"T425","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A426","pred":"mondo_id","subj":"T426","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A427","pred":"mondo_id","subj":"T427","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A428","pred":"mondo_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A429","pred":"mondo_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A430","pred":"mondo_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A431","pred":"mondo_id","subj":"T431","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"SARS-CoV RBD-induced antibodies could cross-react with SARS-CoV-2 RBD and cross-neutralize SARS-CoV-2 pseudovirus infection, indicating that SARS-CoV RBD-specific antibodies may be used for treatment of SARS-CoV-2 infection and that either SARS-CoV RBD protein or SARS-CoV-2 RBD protein may be used as a candidate vaccine to induce cross-reactive or cross-neutralizing antibodies for prevention of SARS-CoV-2 or SARS-CoV infection."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T394","span":{"begin":302,"end":303},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"SARS-CoV RBD-induced antibodies could cross-react with SARS-CoV-2 RBD and cross-neutralize SARS-CoV-2 pseudovirus infection, indicating that SARS-CoV RBD-specific antibodies may be used for treatment of SARS-CoV-2 infection and that either SARS-CoV RBD protein or SARS-CoV-2 RBD protein may be used as a candidate vaccine to induce cross-reactive or cross-neutralizing antibodies for prevention of SARS-CoV-2 or SARS-CoV infection."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T93","span":{"begin":253,"end":260},"obj":"Chemical"},{"id":"T94","span":{"begin":279,"end":286},"obj":"Chemical"}],"attributes":[{"id":"A93","pred":"chebi_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"SARS-CoV RBD-induced antibodies could cross-react with SARS-CoV-2 RBD and cross-neutralize SARS-CoV-2 pseudovirus infection, indicating that SARS-CoV RBD-specific antibodies may be used for treatment of SARS-CoV-2 infection and that either SARS-CoV RBD protein or SARS-CoV-2 RBD protein may be used as a candidate vaccine to induce cross-reactive or cross-neutralizing antibodies for prevention of SARS-CoV-2 or SARS-CoV infection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T133","span":{"begin":0,"end":431},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SARS-CoV RBD-induced antibodies could cross-react with SARS-CoV-2 RBD and cross-neutralize SARS-CoV-2 pseudovirus infection, indicating that SARS-CoV RBD-specific antibodies may be used for treatment of SARS-CoV-2 infection and that either SARS-CoV RBD protein or SARS-CoV-2 RBD protein may be used as a candidate vaccine to induce cross-reactive or cross-neutralizing antibodies for prevention of SARS-CoV-2 or SARS-CoV infection."}